A Clinical Study to evaluate the efficacy of Punica Granatum in Promotion of Cardiovascular Health

CSIR0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•Patients who are willing to undergo for the treatment.
•Age between 20 -70 years.
•Pre-hypertensive patients (as per JNC VII Criteria) and impaired lipid profile.

•Hypertensive patients (SBP>=140mm of Hg and/or DBP>=90mm of Hg).
•Patients with FBS >150mg/dl; PPBS > 200mg/dl; RBS > 250mg/dl.
•Subjects with established diagnosis of CAD requiring any procedure in next 6 months â?? angioplasty or bypass surgery or subjects with New York Heart Association (NYHA) Classification Category III and IV cardiac insufficiency, or any other clinically significant cardiovascular disease.
•Subjects with Haemoglobin percentage < 9 gm% for males and <8gm% for females.
•Patients suffering from major systemic illness necessitating long term treatment (R.A., PTB, malignancy etc.).
•Subjects with concurrent Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit)
•Subject on systemic or oral steroids, oral contraceptive pills or estrogens replacement therapy.
•Any other condition which the Investigator thinks may compromise the safety of the subject.
•Pregnant/ lactating women.
•Patients who have participated in any clinical trial during past 6 months.

发起方

CSIR